[{"id":"9dcadd34-c0bc-43fb-932a-b775ba8fe163","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009329","created_at":"2021-08-17T13:53:05.303Z","updated_at":"2024-07-02T16:34:26.133Z","phase":"Phase 1/2","brief_title":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China","source_id_and_acronym":"NCT05009329","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Airuikai (glecirasib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 311","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"89c3674d-5af4-4476-8421-fecaf79b782e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008288","created_at":"2023-08-23T15:11:14.083Z","updated_at":"2024-07-02T16:35:15.123Z","phase":"Phase 2","brief_title":"A Study of JAB-21822 in Patients With KRAS p.G12C Mutated Pancreatic Cancer","source_id_and_acronym":"NCT06008288","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS • MSI","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12","tags":["KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Airuikai (glecirasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 10/27/2023","start_date":" 10/27/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-03-12"},{"id":"0aaee433-e10e-4960-9df7-8de17cae6f38","acronym":"","url":"https://clinicaltrials.gov/study/NCT05002270","created_at":"2021-08-12T13:54:23.786Z","updated_at":"2024-07-02T16:35:37.783Z","phase":"Phase 1/2","brief_title":"JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation","source_id_and_acronym":"NCT05002270","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Airuikai (glecirasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/03/2021","start_date":" 09/03/2021","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-09-07"},{"id":"a5987937-3183-4133-b867-a1d2653afe5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05194995","created_at":"2022-01-18T12:54:15.051Z","updated_at":"2024-07-02T16:35:53.559Z","phase":"Phase 1/2","brief_title":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation","source_id_and_acronym":"NCT05194995","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Airuikai (glecirasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 02/17/2022","start_date":" 02/17/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-03-10"},{"id":"49802c3e-ce1e-4e25-99ea-df4984c5d29c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05276726","created_at":"2022-03-11T14:53:34.119Z","updated_at":"2024-07-02T16:36:03.348Z","phase":"Phase 1/2","brief_title":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","source_id_and_acronym":"NCT05276726","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12","tags":["KRAS • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Airuikai (glecirasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2022-09-28"},{"id":"dec0e27d-576f-4620-b2f7-4fb083164458","acronym":"JAB-21822-1006","url":"https://clinicaltrials.gov/study/NCT05288205","created_at":"2022-03-21T20:54:45.507Z","updated_at":"2025-02-25T16:17:27.931Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","source_id_and_acronym":"NCT05288205 - JAB-21822-1006","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Airuikai (glecirasib) • sitneprotafib (JAB-3312)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2022-06-30"}]